doi: 10.1080/08830185.2023.2274574 62 FathmanCGYipLGmez-MartnDYuMSeroogyCMHurtCRet al
The reasons for this are: Enhanced Fat Oxidation L-Carnitine helps in the transport of long-chain fat acids into mitochondria where they are oxidized and used as energy during the activity
Retatrutide vs Classic Weight-Loss Medications Older medications like phentermine, orlistat, and naltrexone/bupropion cannot match retatrutides metabolic efficiency
The class began with semaglutide near 15 percent, advanced to the dual agonist tirzepatide near 21 percent, and now reaches the triple agonist retatrutide above 28 percent, while oral pills and monthly injectables crowd in behind them
In 2026, two oral GLP-1 receptor agonists are positioned to reshape this market: **oral semaglutide** (approved for weight loss in December 2025) and **orforglipron** (Eli Lilly's non-peptide candidate expected to receive an FDA decision by mid-to-late 2026)
[DOI] [PMC free article] [PubMed] [Google Scholar] Xu C., Li E., Liu Y., Wang S., Wang X., Chen K., et al